Clovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing Looms

• Clovis Oncology Inc (NASDAQ: CLVS) posted a Q3 EPS loss of $(0.39), up from $(0.56) a year ago, on sales of $30.66 million, down from $37.92 million.

• The shares tanked after the company noted bankruptcy concerns in its Q3 SEC filing.

• Based on current cash and cash equivalents of $58.30 million and estimates for Rubraca revenues, the company will not have sufficient liquidity to maintain operations beyond January 2023.

• Last quarter, Clovis raised the need for additional capital to continue beyond February 2023.

• Related: Clovis Oncology's Rubraca Hits Primary Goal In Prostate Cancer Settings.

• Operating losses and negative cash flows are expected to continue for the foreseeable future, even with Rubraca generating revenues.

• Rubraca revenues have not been consistent in prior quarters and have been trending downward during the past two years, initially due to the COVID-19 pandemic on patient visits and diagnoses, but more recently due to competition from other products on the market.

• The company is in active discussions on a potential sub-licensing arrangement for Rubraca outside the U.S., but the regulatory uncertainty has made it more difficult to reach an agreement on financial terms.

• Clovis is also in active discussions to sell license rights to FAP-2286.

• Price Action: CLVS shares are down 75.60% at $0.24 on the last check Wednesday.

See more from Benzinga

• PolarityTE Shares Jump After Non-Binding Buyout Offer Of $1.25/Share

• FDA Adcomm Backs AstraZeneca's 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids

• Crypto Collapse: Why Bitcoin And Ethereum Are Crashing - Bitcoin (BTC/USD)

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.